Cancer Research SABCS  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3682-3689, July 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traganos, F.
Right arrow Articles by Darzynkiewicz, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traganos, F.
Right arrow Articles by Darzynkiewicz, Z.

Caffeine Modulates the Effects of DNA-intercalating Drugs in Vitro: A Flow Cytometric and Spectrophotometric Analysis of Caffeine Interaction with Novantrone, Doxorubicin, Ellipticine, and the Doxorubicin Analogue AD1981

Frank Traganos2, Jan Kapuscinski and Zbigniew Darzynkiewicz

The Cancer Research Institute, New York Medical College, Elmsford, New York 10523

Exposure of L1210 cells to DNA-intercalating antitumor drugs Novantrone (mitoxantrone; 20 ng/ml), doxorubicin (0.5 µg/ml), ellipticine (5 µg/ml), or the doxorubicin analogue AD198 (0.4 µg/ml), for 1 h, results in inhibition of cell proliferation, arrest of cells in the G2 phase of the cell cycle, and an increase in the number of cells entering higher DNA ploidy. These effects are significantly reduced when 5 mM concentrations of the methylxanthines caffeine or pentoxifylline are present either simultaneous with, or, in some cases, when added for 1 h immediately following pulse exposure to the drug. Both caffeine and pentoxifylline alone (5 mM) have little effect on cell growth or cell cycle progression. The possible mechanism of cell protection against intercalating drugs provided by caffeine was studied spectrophotometrically by measuring the interaction between Novantrone and the caffeine chromophore and in a model system using permeabilized L1210 cells and measuring the effect of caffeine in reducing binding of the intercalating dye acridine orange to cellular DNA and RNA. The data indicate that the observed protection of cells against intercalating drugs by caffeine or pentoxifylline is most likely a consequence of the direct interaction between the methylxanthines and the planar aromatic molecules of the intercalating drugs: formation of caffeine-drug complexes in solution effectively lowers the concentration of the free drug and thereby reduces its pharmacological activity. The principle of selective entrapment of the intercalator by compounds like caffeine may be considered in designing strategies to modulate the activity of intercalating drugs in vivo, e.g., in lowering drug toxicity when inadvertently applied at too high doses.

1 This work was supported by U.S.P.H.S. Grants R37 CA 23296 and CA28704, as well as the Carl Inserra Fund.

2 To whom requests for reprints should be addressed, at The Cancer Research Institute, 100 Grasslands Road, Elmsford, NY 10523.

Received 3/ 1/91. Accepted 5/ 7/91.




This article has been cited by other articles:


Home page
ANN BOT (LOND)Home page
M. NOIROT, P. BARRE, C. DUPERRAY, J. LOUARN, and S. HAMON
Effects of Caffeine and Chlorogenic Acid on Propidium Iodide Accessibility to DNA: Consequences on Genome Size Evaluation in Coffee Tree
Ann. Bot., August 1, 2003; 92(2): 259 - 264.
[Abstract] [Full Text] [PDF]


Home page
J. Epidemiol. Community HealthHome page
G Lopez-Abente and A Escolar
Tobacco consumption and bladder cancer in non-coffee drinkers
J Epidemiol Community Health, January 1, 2001; 55(1): 68 - 70.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.